Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44 results about "Monoamine oxidase B inhibitors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B).
Lithium combinations, and uses related thereto
InactiveUS20050233010A1Prevent precipitating manic episodeLessening and preventing riskBiocideNervous disorderPsychoactive drugAdrenergic antagonist
The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.
Owner:NOVEN THERAPEUTICS
Mao-b inhibitors useful for treating obesity
The invention provides novel compounds of formula I: that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
Owner:JENRIN DISCOVERY
Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
InactiveUS20030087814A1Increase ratingsDelaying resumptionBiocideNervous disorderAldehyde Dehydrogenase InhibitorAlcoholisms
Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.
Owner:KRELE PHARMACEUTICALS INC
Lithium combinations, and uses related thereto
InactiveUS20080107756A1Prevent precipitating manic episodeLessening and preventing riskBiocideNervous disorderNorepinephrine reuptake inhibitorPsychoactive drug
The present invention relates to combinatorial therapies for treating anxiety, depression or psychotic conditions using a lithium salt and a psychoactive drug selected from the group consisting of serotonin reuptake inhibitor, a 5HT2 receptor antagonist, an anticonvulsant, a norepinephrine reuptake inhibitor, an α-adrenoreceptor antagonist, an NK-3 antagonist, an NK-1 receptor antagonist, a PDE4 inhibitor, an Neuropeptide Y5 Receptor Antagonists, a D4 receptor antagonist, a 5HT1A receptor antagonist, a 5HT1D receptor antagonist, a CRF antagonist, a monoamine oxidase inhibitor, a sedative-hypnotic drug, and an atypical antipsychotic.
Owner:NOVEN THERAPEUTICS
Substituted picolinamides as MAO-B inhibitors useful for treating obesity
The invention provides novel compounds of formula I:that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
Owner:JENRIN DISCOVERY
Mao-b inhibitors useful for treating obesity
The invention provides novel compounds of formulae I and II:
that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
Owner:JENRIN DISCOVERY
Use of beggarweed alkaloid monomer component
InactiveCN103816150AStrong inhibitory activityImproved stress behaviorOrganic active ingredientsNervous disorderAmine oxidase inhibitorsPharmaceutical drug
The invention discloses use of a beggarweed alkaloid monomer component. A beggarweed alkaloid monomer contains bufotenin, 5-Hydroxy-N,N-dimethyltryptamineN12-oxide and 5-methoxy-N,N-dimenthyl tryptamine. The use of the beggarweed alkaloid monomer component is used for preparing a monoamine oxidase inhibitor, namely the use in preparation of a medicament for preventing and treating depressive disorder and Parkinsonism.
Owner:LANZHOU UNIVERSITY OF TECHNOLOGY
Medicinal compositions
ActiveUS20060241102A1Shorten the construction periodEffective treatmentBiocideNervous disorderTricyclic antidepressantAmine oxidase inhibitors
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
MAO-B inhibitors useful for treating obesity
The invention provides novel compounds of formulae I and II:that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and / or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
Owner:JENRIN DISCOVERY
MAO-B inhibitors useful for treating obesity
The invention provides novel compounds of formulae I and II:
that are monoamine oxidase-B inhibitors, which can be useful in treating obesity, diabetes, and/or cardiometabolic disorders (e.g., hypertension, dyslipidemias, high blood pressure, and insulin resistance).
Owner:JENRIN DISCOVERY
Application of liquidambar formosana hance fruit tannin monomer
InactiveCN102743367AOrganic active ingredientsNervous disorderGallic acid esterAmine oxidase inhibitors
The invention relates to applications of liquidambar formosana hance fruit tannin monomer. The monomer comprises the components of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate. The invention relates to the application of the monomer in preparing a monoamine oxidase inhibitor. The invention is characterized in that the invention relates to the applications of gallic acid, ethyl gallate, p-digalloyl acid, and ethyl-p-digallate in preparing medicines used for treating depression and Parkinson's disease.
Owner:LANZHOU UNIVERSITY OF TECHNOLOGY
Beta-carboline selective monoamine oxidase B inhibitor and pharmaceutical application thereof
The invention discloses beta-carboline derivatives with structural characteristics shown in a formula (I), and also discloses pharmaceutically acceptable salts of the beta-carboline derivatives, a preparation method of the beta-carboline derivatives and application of the beta-carboline derivatives as selective monoamine oxidase B inhibitors. The compounds of the invention are useful for the treatment of neuropsychiatric and degenerative diseases modulated by selective monoamine oxidase B inhibitors, including Parkinson's disease, Alzheimer's disease, obsessive-compulsive disorder, depression, schizophrenia, anorexia nervosa and migraine.
Owner:陈冬寅
Treatment of muscular dystrophies and associated conditions by administration of monoamine oxidase inhibitors
Administration of a monoamine oxidase inhibitor is useful in the prevention and treatment of muscle dystrophy. Methods and compositions for inhibiting the production of reactive oxygen species in a muscle cell overproducing reactive oxygen species are provided herein.
Owner:UNIV DEGLI STUDI DI PADOVA
Tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives and preparation method and application thereof
The invention discloses tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives of which the structure is shown in a general formula of a figure in the abstract. The invention simultaneously discloses the preparation method of the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives. The invention further discloses the application of the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives as a reversible and selective monoamine oxidase inhibitor drug, specifically, the tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine can be applied to drugs or drug compositions for treating and preventing diseases related to aging, alzheimer's disease and parkinson's disease.
![Tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/b0a97f89-d403-4c8b-baa9-54071c6e057c/150901091621.PNG "Tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives and preparation method and application thereof")
![Tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/b0a97f89-d403-4c8b-baa9-54071c6e057c/540051DEST_PATH_IMAGE002.PNG "Tricyclo-pyrazole [1,5-d] [1,4] benzo oxazepine-one derivatives and preparation method and application thereof")
Owner:汤文建
Neuroprotective and neuro-restorative iron chelators and monoamine oxidase inhibitors and uses thereof
8-Hydroxy-quinoline derivatives and 8-ethers, 8-esters, 8-carbonates, 8-acyloxymethyl, 8-phosphates, (phosphoryloxy)methyl, and 8-carbamates derivatives thereof are described that exhibit iron chelation, neuroprotective, neurorestorative, apoptotic and / or selective MAO-AB inhibitory activities.
Owner:ZURAWSKI JR VINCENT R +4
Monoamine oxidase B inhibitor with potential iron chelating activity and application thereof
According to the invention, a monoamine oxidase inhibitor with iron ion chelating activity is synthesized, and a pyridone derivative with iron ion chelating activity and a chromone mother nucleus with MAO-B inhibitory activity are innovatively and organically combined together; the compound has remarkable advantages on neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease with complex pathogenesis.
Owner:ZHEJIANG UNIV OF TECH
Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
InactiveUS20050106241A1Avoid disadvantagesImproves ease and convenienceBiocideOrganic active ingredientsGastric AbsorptionMetabolite
The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and / or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing.
Owner:CATALENT USA WOODSTOCK INC +2
Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
InactiveUS20090005441A1Increase ratingsDelaying resumptionBiocideNervous disorderAlcoholismsAldehyde Dehydrogenase Inhibitor
Compositions and methods for treating, preventing, or reducing alcoholism, in particular methods for increasing patient compliance with therapies that require the intake of an ALDH inhibitor comprising the step of administering a monoamine oxidase B inhibitor.Owner:KRELE PHARMACEUTICALS INC
Pharmaceutical composition
InactiveUS8034820B2Effective treatmentShorten the construction periodBiocideNervous disorderTricyclic antidepressantPurine
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject
ActiveUS11083718B2Useful in treatmentReduce in quantityOrganic active ingredientsNervous disorderDepressantPharmaceutical medicine
A first aspect of the invention relates to betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject. A second aspect of the invention relates to a method of treating or preventing one or more symptoms of vertigo in a subject, said method comprising administering to the subject (i) betahistine, or a pharmaceutically acceptable salt thereof, and (ii) a monoamine oxidase inhibitor.
Owner:INTRABIO LTD
Methods of treating depression
The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and / or different CYP2D6 metabolizer status.
Owner:RUNDLE RES LLC
Application of a kind of coumarin compound in the preparation of monoamine oxidase inhibitor
InactiveCN108478568BNervous disorderHeterocyclic compound active ingredientsAmine oxidase inhibitorsMonoamine Oxidase A Gene
The invention discloses a purpose of a coumarin compound shown as a general formula (I) in preparation of a monoamine oxidase inhibitor, which belongs to the technical field of a medicine. Through in-vitro enzyme activity tests, the compound has good inhibition activity for monoamine oxidases A and B, and provides reference and novel thinking for developing the novel MAO inhibitor.
Owner:HUAZHONG AGRI UNIV
A kind of selenium-containing benzobisfuran compound and its preparation and application
ActiveCN104193757BGood monoamine oxidase inhibitory activityStrong inhibitory activityOrganic chemistryFuranAryl
Selenium-containing benzobisfuran type compounds and preparation and applications thereof are disclosed. The structure formulas of the compounds are shown as a formula (X-a), a formula (X-b) and a formula (X-c), wherein R1 is a ketone group, an ester group or a cyano group, and R2 is C1-C6 alkyl, C1-C6 haloalkyl or aryl. A preparing route of the compounds is shown as follows. The compounds have good monoamine oxidase inhibitory activity and can be used for preparing monoamine oxidase inhibitors.
Owner:ZHEJIANG UNIV OF TECH
A kind of synthetic method of novel monoamine oxidase inhibitor morabetamide
ActiveCN109422675BRaw materials are easy to getThe reaction circuit is simpleOrganic chemistryDrug compositionsMorpholineCarboxylic acid
The invention discloses a method for synthesizing morabetamide, a novel monoamine oxidase inhibitor, which uses 5-chloro-2-pyridinecarboxylic acid as a starting material, first generates 5-chloro-2-pyridinecarboxylic acid chloride through acid chloride reaction, and then After amidation reaction, 5-chloro-N-(2-hydroxyethyl)-2-pyridinecarboxamide is generated, and finally condensed with morpholine to generate morapetamide. The compound morabetamine of the present invention adopts ethanolamine, 5-chloro-2-pyridine carboxylic acid and morpholine as main raw materials to prepare the novel monoamine oxidase inhibitor morabetamide, and the raw materials are easy to obtain. The production of morabetamide by the above method has the advantages of simple operation, good product purity and high yield, and is suitable for industrialized production.
Owner:CHONGQING NORMAL UNIVERSITY
Treatment for dopaminergic disorders
ActiveUS20140309260A1Delay disease progressionSide effectBiocideAnimal repellantsOxidative enzymePharmacology
The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Cav1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).
Owner:NORTHWESTERN UNIV
Use of a 1,3-benzoxathiol-2-one compound in the preparation of monoamine oxidase inhibitors
InactiveCN108379260BNervous disorderHeterocyclic compound active ingredientsMonoamine Oxidase Type BAmine oxidase inhibitors
The invention discloses an application of 1,3-benzoxazolethiol-2-one compounds, which are shown as Formula (I), in preparing a monoamine oxidase inhibitor. Based upon in-vitro enzymatic activity experimental tests, it is indicated that the compounds have good inhibitory activity on both monoamine oxidase A and monoamine oxidase B; therefore, a reference and a new thought are provided and developedfor the development of the novel MAO inhibitor (monoamine oxidase inhibitor) (shown as the Description).
Owner:HUAZHONG AGRI UNIV
Medicinal composition
The invention relates to a pharmaceutical composition comprising Morinda officinalis oligosaccharide extract and a non-sugar antidepressant as active components. It is characterized in that the total content of inulin-type oligosaccharides in the extract of Morinda officinalis oligosaccharides is 50-70%, and the content of inulin-type pentameric oligosaccharides is 5-15%; non-sugar antidepressants include Monoamine oxidase inhibitor antidepressant drugs such as moclobemide, norepinephrine reuptake inhibitor antidepressant drugs such as imipramine, amitriptyline, maprotiline, doxepin, clomipa antidepressants such as fluoxetine, paroxetine, sertraline or citalopram, etc., or dual norepinephrine / selective serotonin Non-carbohydrate antidepressants of the reuptake inhibitor class, such as mirtazapine, duloxetine, venlafaxine, or desmethylvenlafaxine. The present invention also relates to the use of the pharmaceutical composition of Morinda officinalis oligosaccharide extract and a non-saccharide antidepressant drug as active ingredients in treating neuropsychiatric diseases such as depression, anxiety, and neurogenic pain.
Owner:BEIJING MEIBEITA DRUG RES
Methods of treating depression with vortioxetine
InactiveUS20220202809A1Reduce eliminateReduce riskOrganic active ingredientsNervous disorderDepressantBlood plasma
The present disclosure relates to methods of transitioning patients or obese patients being treated with vortioxetine to treatment with a monoamine oxidase inhibitor (MAOI). The methods provided include delaying administration of the MAOI for certain time periods after stopping administration of vortioxetine. The patients or obese patients possess various capabilities of metabolizing vortioxetine. The current disclosure also includes methods of switching patients to a MAOI intended to treat psychiatric disorders while being treated with vortioxetine. The methods disclosed further comprise determining vortioxetine plasma clearance and washout time for patients with different body fat status and / or different CYP2D6 metabolizer status.
Owner:RUNDLE RES LLC
A kind of preparation method of monoamine oxidase inhibitor
ActiveCN105693515BImprove securityNatural Sources ExpansionNervous disorderMicroorganism based processesAmine oxidase inhibitorsOxidative enzyme
The invention discloses a preparation method of a monoamine oxidase inhibitor. The preparation method comprises following steps: (1) ethyl alcohol is used for precipitating a lactobacillus fermentation broth, and a supernatant is collected; (2) water and ethyl acetate are added into the supernatant for extraction, an obtained ethyl acetate phase extracting solution is subjected to evaporation so as to remove the solvent and obtain an ester phase extract; and (3) the ester phase extract obtained in step (2) is subjected to column chromatography positive phase elution. The monoamine oxidase inhibitor is prepared from natural products, is obtained via separation purification from lactobacillus fermentation products, is low in toxicity, high in safety, and possesses a promising application prospect.
Owner:BRIGHT DAIRY & FOOD CO LTD
Monoamine oxidase b inhibitors for use in prevention or treatment of prostate cancer
PendingCN114375203AOrganic active ingredientsAntineoplastic agentsMonoamine Oxidase Type BProstate cancer
The present invention provides a monoamine oxidase B (MAO-B) inhibitor compound for use in the prevention or treatment of prostate cancer (PCa) wherein a selective MAO-A inhibitor compound is not co-administered. In use, other agents for the treatment of prostate cancer are administered together or alternately with the selective compound MAO-B, and/or radiation therapy is used together or alternately with the selective compound MAO-B for the treatment of prostate cancer. A further aspect of the invention is the use of MAO-B inhibitor compounds in the manufacture of a medicament for the treatment of prostate cancer.
Owner:TOXIE EURO INTELLIGENS KÉMIAI SZENZOROKAT KUTATÓ, FEJLESZTÓ KORLÁTOLT FELELÓSSEGÚ TÁRSASÁG
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap